GHCM
TVRD

Glen Harbor Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Glen Harbor Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-76
Closed -$34K – 1309
2018
Q1 		$34K Sell
76
-229
-75% -$111K ﹤0.01% 1252
2017
Q4 		$134K Sell
305
-181
-37% -$82.5K ﹤0.01% 1098
2017
Q3 		$240K Sell
486
-61
-11% -$30.5K 0.01% 837
2017
Q2 		$303K Sell
547
-182
-25% -$115K 0.01% 734
2017
Q1 		$482K Hold
729
– – 0.01% 564
2016
Q4 		$244K Buy
+729
New +$234K 0.01% 663

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Glen Harbor Capital Management's TVRD Position: Q2 2018 in Review

Glen Harbor Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2018, closing a stake of 76 shares — an estimated $34K sold.

Glen Harbor Capital Management first reported a position in TVRD in Q4 2016 and held it in 6 quarters. The position peaked at $482K in Q1 2017. 130 funds tracked by Wall St. Rank hold TVRD as of Q2 2018.

  • Glen Harbor Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Glen Harbor Capital Management sold 76 Tvardi Therapeutics shares in Q2 2018, an estimated $34K.
  • Glen Harbor Capital Management first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 6 quarters.
  • Glen Harbor Capital Management's Tvardi Therapeutics position peaked at $482K in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2018.

Based on Glen Harbor Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.